FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

This includes a detailed review of ongoing and upcoming studies that are set to shape the future of Pulmonary Arterial Hypertension treatment. With its rich data and forward-looking insights ...

To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Forecast ...

The company was testing its therapy, cibotercept, in patients with pulmonary arterial hypertension (PAH) - a rare disease ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

A new molecular imaging technique-18F-FAPI PET-can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker ...

F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

A new phase 3 study comparing mono and duo therapies may yield greater guidance and treatment options for children with pulmonary arterial hypertension (PAH). PAH is a rare condition in children ...